Revision surgery versus biologic treatment with omalizumab in recurrent chronic rhinosinusitis with nasal polyps: An analysis of cost-utility and clinical outcomes.

"Declaration of competing interest All the authors declare that they have no conflicts of interest related to the contents of this work."

"Funding This project was supported by the National Key R&D Program of China (2022YFC2504100), the Program for the Changjiang Scholars and Innovative Research Team (IRT13082), the 10.13039/100014717National Natural Science Foundation of China (82171110, 82000962, and 81970852), the CAMS Innovation Fund for Medical Sciences (2019-I2M-5–022), the Capital's funds for health improvement and research (2022-1-1091), the Beijing Natural Science Foundation (7222024), the Beijing New-star Plan of Science and Technology (20220484226), the Beijing Hospitals Authority Youth Program (QML20230201), the Public Welfare Development and Reform Pilot Project (2019-10), the Beijing Municipal Science & Technology Commission (Z211100002921057) and the Special Funds for the Construction of High-level Public Health Technical Talents (Lingjunrencai-01-08 and Lingjunrencai-02-09)."